Business
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of PH/PAH CUPERTINO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent EP3244896 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of PH, adding to its existing patent protection in key markets around the world including the United States, China and Japan. The European patent covers brilaroxazine use for treating PH and PAH in any patients and treating PH in patients with COPD or SCD. Brilaroxazine has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of PAH. “This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO. “Brilaroxazine has demonstrated a favorable clinical safety and tolerability profile in over 800 subjects to date from multiple clinical trials. A significant reduction in key proinflammatory biomarkers following brilaroxazine treatment was recently shown in a large, global, pivotal Phase 3 study in patients with schizophrenia. Building on this promising clinical data, potent anti-inflammatory and antifibrotic activities and significant reduction in pulmonary arterial pressure has been shown in translational animal models for PAH following brilaroxazine treatment, and we look forward to further evaluating brilaroxazine’s unique multi-modal mechanism of action with clinical development expansion opportunities in PH and PAH.” About BrilaroxazineBr...